Skip to main content

Beta-Thalassemia

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia
NCT04938635 | PHASE 2 | INTERVENTIONAL

The main purpose of this study is to evaluate the efficacy of 3 multiple doses of VIT-2763 as measured by the reduction in red blood cell (RBC) transfusion burden from Week 13 to Week 24, to identify the most efficacious and safe dose.

Trial Information
7 Sites
0 Participants
WITHDRAWN
18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Investigator site #
Whittier,California,United States,90603
Investigational site #
Plovdiv,California,Bulgaria,90603-2137
Investigational site #
Sofia,California,Bulgaria,90603-2137
Investigational site #
Stara Zagora,California,Bulgaria,90603-2137
Investigator Site
Jerusalem,California,Israel,90603-2137
Investigator Site
Petah tikva,California,Israel,90603-2137
Investigator Site
Safed,California,Israel,90603-2137

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov